Quantitative proteomics reveals the mechanisms of hydrogen-conferred protection against hyperoxia-induced injury in type II alveolar epithelial cells

Xue, Lingxiao; Wang, Chao; Wu, Dan; Zhang, Chao; Xiao, Changxue; Xu, Feng

doi:10.1080/01902148.2019.1601296

Cited by 7 publications

(6 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Protein mass spectrometry had been applied to some experimental studies regarding BPD 29 , 30 , and clinical research by DIA indicated that calcium-associated proteins can be used as sensitive markers for BPD progress 31 . In this study, the results revealed that a total of 52 proteins were differentially expressed before and after dexamethasone treatment.…”

Section: Discussionmentioning

confidence: 99%

A clinical study on plasma biomarkers for deciding the use of adjuvant corticosteroid therapy in bronchopulmonary dysplasia of premature infants

et al. 2021

View full text Add to dashboard Cite

Objective: The study was designed to investigate some plasma markers which help us to decide the use of adjuvant corticosteroid therapy in bronchopulmonary dysplasia (BPD) of premature infants. Methods: Thirty BPD infants were treated by dexamethasone. Among these cases, dexamethasone was significant effective in 10 cases, and no significant effective in 20 cases. These patients were divided into two groups as the significant effect (SE) group (n=10) and the non-significant effect (NE) group (n=20) according to the curative effect of dexamethasone. Fifteen non-BPD infants with gestational age and gender matching were selected as the control group. Plasma samples before and after dexamethasone treatment were collected from three infants chosen randomly from SEG for the data-independent acquisition (DIA) analysis. ELISA was further used to detect the levels of differential proteins LRP1 and S100A8 in all individuals, including SE, NE and control groups. Results: DIA analysis results showed that after dexamethasone treatment, there were a total of 52 plasma proteins that showed significant differences, of which 43 proteins were down-regulated and 9 proteins were up-regulated. LRP1 and S100A8 were two plasma proteins that were significantly changed after dexamethasone treatment. Compared with the control group, plasma LRP1 was significantly increased in BPD. Interestingly, the plasma concentration of LRP1 in the NE group was significantly higher than that in the SE group. S100A8, as an indicator of plasma inflammation, was significantly higher in BPD than the control group. Unlike LRP1, there was no significantly difference between the SE and NE group (P=0.279) before dexamethasone treatment. Conclusion: Elevated plasma LRP1 and S100A8 in BPD infants are two indicators that correlated with the efficacy of dexamethasone, and might be used as biomarkers for deciding the use of adjuvant corticosteroids therapy in the BPD.

show abstract

Section: Discussionmentioning

confidence: 99%

A clinical study on plasma biomarkers for deciding the use of adjuvant corticosteroid therapy in bronchopulmonary dysplasia of premature infants

et al. 2021

View full text Add to dashboard Cite

show abstract

“…To further understand the molecular mechanisms underlying molecular hydrogen effects in HILI, quantitative proteomics in vitro revealed that molecular hydrogen can protect AECIIs from hyperoxic injury by modulating a range of protein expression levels and biological processes, such as VEGFA, PDGFB, IGFBP3, EDN1, NADPH oxidase levels, and the coagulation cascade (Lu et al 2018). These findings provide a theoretical basis for the clinical application of molecular hydrogen in treating oxygen toxicity.…”

Section: Hyperoxia-induced Acute Lung Injurymentioning

confidence: 96%

Molecular hydrogen is a potential protective agent in the management of acute lung injury

Zhang

2022

Mol Med

View full text Add to dashboard Cite

Acute lung injury (ALI) and acute respiratory distress syndrome, which is a more severe form of ALI, are life-threatening clinical syndromes observed in critically ill patients. Treatment methods to alleviate the pathogenesis of ALI have improved to a great extent at present. Although the efficacy of these therapies is limited, their relevance has increased remarkably with the ongoing pandemic caused by the novel coronavirus disease 2019 (COVID-19), which causes severe respiratory distress syndrome. Several studies have demonstrated the preventive and therapeutic effects of molecular hydrogen in the various diseases. The biological effects of molecular hydrogen mainly involve anti-inflammation, antioxidation, and autophagy and cell death modulation. This review focuses on the potential therapeutic effects of molecular hydrogen on ALI and its underlying mechanisms and aims to provide a theoretical basis for the clinical treatment of ALI and COVID-19.

show abstract

“… [87] AT2 cells is also widely acknowledged as a main progenitor cell in the alveoli. [83] , [84] , [85] , [86] , [88] , [89] , [90] , [91] , [92] , [93] , [94] , [95] , [96] AT2 cells are composed of heterogeneous subpopulations that express different markers and possess unequal regenerative capacity. [97 , 98] For example, the subpopulation highly expressing CD44 acts as progenitor cells during the steady state, [98] whereas the Sca1-positive subpopulation exhibits higher regenerative potential than the Sca1-negetive subpopulation, which is reported to mediate alveolar regeneration following both Pseudomonas aeruginosa (PA) and bleomycin-induced lung injury.…”

Section: Pulmonary Endogenous Stem Cellsmentioning

confidence: 99%

“…Molecular hydrogen exhibited protective roles against hyperoxia-induced lung injury by promoting AT2 cells differentiation, which may be associated with VEGFA, PDGFB, IGFBP3, EDN1, NADPH oxidase, and the coagulation cascade. [96] Notably, underlying mechanisms balancing AT2 cells proliferation and differentiation have been partly revealed. Fgfr2 was found to promote AT2 cells proliferation but inhibit differentiation in actively repairing areas after acute influenza injury, thus restoring normal alveolar structure and function.…”

Section: Pulmonary Endogenous Stem Cellsmentioning

confidence: 99%

Pulmonary endogenous progenitor stem cell subpopulation: Physiology, pathogenesis, and progress

Liu

Jiang

et al. 2023

Journal of Intensive Medicine

View full text Add to dashboard Cite

Quantitative proteomics reveals the mechanisms of hydrogen-conferred protection against hyperoxia-induced injury in type II alveolar epithelial cells

Cited by 7 publications

References 23 publications

A clinical study on plasma biomarkers for deciding the use of adjuvant corticosteroid therapy in bronchopulmonary dysplasia of premature infants

A clinical study on plasma biomarkers for deciding the use of adjuvant corticosteroid therapy in bronchopulmonary dysplasia of premature infants

Molecular hydrogen is a potential protective agent in the management of acute lung injury

Pulmonary endogenous progenitor stem cell subpopulation: Physiology, pathogenesis, and progress

Contact Info

Product

Resources

About